Nanoencapsulated doxorubicin prevents mucositis development in mice

Página do item simplificado
dc.creatorCristiane M. Pinto
dc.creatorLaila S. Horta
dc.creatorAmanda P. Soares
dc.creatorBárbara A. Carvalho
dc.creatorEnio Ferreira
dc.creatorEduardo B. Lages
dc.creatorLucas A. M. Ferreira
dc.creatorAndré A. G. Faraco
dc.creatorHelton C. Santiago
dc.creatorGisele A. C. Goulart
dc.date.accessioned2025-01-22T21:30:48Z
dc.date.accessioned2025-09-09T01:10:17Z
dc.date.available2025-01-22T21:30:48Z
dc.date.issued2021-07-04
dc.identifier.doihttps://doi.org/10.3390/pharmaceutics13071021
dc.identifier.issn1999-4923
dc.identifier.urihttps://hdl.handle.net/1843/79417
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofPharmaceutics
dc.rightsAcesso Aberto
dc.subjectQuimioterapia
dc.subjectMedicamentos
dc.subjectInfusões intravenosas
dc.subjectMateriais nanoestruturados
dc.subject.otherNanostructured lipid carriers
dc.subject.otherDoxorubicin
dc.subject.otherMucositis
dc.titleNanoencapsulated doxorubicin prevents mucositis development in mice
dc.typeArtigo de periódico
local.citation.epage18
local.citation.issue7
local.citation.spage1
local.citation.volume13
local.description.resumoDoxorubicin (DOX), a chemotherapy drug successfully used in the therapy of various types of cancer, is currently associated with the mucositis development, an inflammation that can cause ulcerative lesions in the mucosa of the gastrointestinal tract, abdominal pain and secondary infections. To increase the safety of the chemotherapy, we loaded DOX into nanostructured lipid carriers (NLCs). The NLC–DOX was characterized by HPLC, DLS, NTA, Zeta potential, FTIR, DSC, TEM and cryogenic-TEM. The ability of NLC–DOX to control the DOX release was evaluated through in vitro release studies. Moreover, the effect of NLC–DOX on intestinal mucosa was compared to a free DOX solution in C57BL/6 mice. The NLC–DOX showed spherical shape, high drug encapsulation efficiency (84.8 ± 4.6%), high drug loading (55.2 ± 3.4 mg/g) and low average diameter (66.0–78.8 nm). The DSC and FTIR analyses showed high interaction between the NLC components, resulting in controlled drug release. Treatment with NLC–DOX attenuated DOX-induced mucositis in mice, improving shortening on villus height and crypt depth, decreased inflammatory parameters, preserved intestinal permeability and increased expression of tight junctions (ZO-1 and Ocludin). These results indicated that encapsulation of DOX in NLCs is viable and reduces the drug toxicity to mucosal structures.
local.identifier.orcidhttps://orcid.org/0009-0002-0089-2857
local.identifier.orcidhttps://orcid.org/0000-0002-1835-0303
local.identifier.orcidhttps://orcid.org/0000-0002-2458-6021
local.identifier.orcidhttps://orcid.org/0000-0003-2474-5536
local.identifier.orcidhttps://orcid.org/0000-0002-2344-6158
local.identifier.orcidhttps://orcid.org/0000-0002-5695-8256
local.identifier.orcidhttps://orcid.org/0000-0003-0292-076X
local.publisher.countryBrasil
local.publisher.departmentFAR - DEPARTAMENTO DE PRODUTOS FARMACÊUTICOS
local.publisher.departmentICB - DEPARTAMENTO DE BIOQUÍMICA E IMUNOLOGIA
local.publisher.initialsUFMG
local.url.externahttps://www.mdpi.com/1999-4923/13/7/1021

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Nanoencapsulated doxorubicin prevents mucositis development in mice.pdf
Tamanho:
2.63 MB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG